by Alison Kanski
NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more
by Jonah Fieldman
The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.
The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results, according to data
by Ariana Pelosci
Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.
Patients with advanced solid tumors who have ATM gene alterations
by the ASCO Post Staff
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel antibody-drug conjugate therapy produced a substantially better response than standard treatments, investigators from Dana-Farber Cancer Institute reported at the … Read more
by Gina Mauro
The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.
The use
by Hayley Virgil
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses
by Anne Doerr
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more
A drug currently used to treat skin and lung cancers has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found.
As a … Read more
by Julie S. Brokaw
A patient with ovarian cancer describes how she enrolled in a clinical trial, and how it has given her a renewed sense of hope that she may find a successful treatment option.
To find clinical trials,
… Read moreby Ariana Pelosci
Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.
A combination regimen of paclitaxel
… Read moreby Kristi Rosa
The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.
The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced
by Nichole Tucker
Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant
By Courtney Marabella
The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.
The addition of a short-term,
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
by Kelly Irvin
The number one reason to participate in a clinical trial is because someone has to do it so new drugs can be developed to treat and even cure cancer. All of the drugs we have now were … Read more
By Alan P. Lyss, MD
The COVID-19 pandemic prompted changes to standard practices for cancer clinical trials, and thought leaders have recommended continuing — and improving upon — those new practices.
These recommendations, from members of the American Association for … Read more
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more
